Dialysis News and Research

Latest Dialysis News and Research

UIC introduces robotic kidney transplantation surgery for obese recipients

UIC introduces robotic kidney transplantation surgery for obese recipients

17 Dec 2010
Study: Natural high hemoglobin levels safe for kidney disease patients on dialysis

Study: Natural high hemoglobin levels safe for kidney disease patients on dialysis

17 Dec 2010
State roundup: Minn. to add more adults to Medicaid; Mass. Gov. seeks savings in pensions and health care costs; Ariz. bishop and hospital spar over control

State roundup: Minn. to add more adults to Medicaid; Mass. Gov. seeks savings in pensions and health care costs; Ariz. bishop and hospital spar over control

16 Dec 2010
Davita launches online tool for dialysis patients

Davita launches online tool for dialysis patients

15 Dec 2010
Research: Kidney disease caused by autoimmune disease lupus may be twice as lethal in children

Research: Kidney disease caused by autoimmune disease lupus may be twice as lethal in children

13 Dec 2010
In effort to curb preventable ICU infections, new reporting requirement kicks in Jan. 1

In effort to curb preventable ICU infections, new reporting requirement kicks in Jan. 1

10 Dec 2010
Low phosphate diets may increase dialysis patients' risk of premature death

Low phosphate diets may increase dialysis patients' risk of premature death

10 Dec 2010
Mortality is higher in for-profit than non-profit dialysis centers, says study

Mortality is higher in for-profit than non-profit dialysis centers, says study

9 Dec 2010
Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

8 Dec 2010
Three abstracts on Defibrotide presented at ASH Annual Meeting

Three abstracts on Defibrotide presented at ASH Annual Meeting

8 Dec 2010
Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

7 Dec 2010
Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

6 Dec 2010
Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

6 Dec 2010
Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

2 Dec 2010
Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

1 Dec 2010
NxStage Medisystems division commences distribution through Metro Medical

NxStage Medisystems division commences distribution through Metro Medical

30 Nov 2010
Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

30 Nov 2010
BioTrends releases annual syndicated publication of CKD-ND patient charts

BioTrends releases annual syndicated publication of CKD-ND patient charts

30 Nov 2010
FG-2216 drug offers new treatment option for kidney disease-related anemia

FG-2216 drug offers new treatment option for kidney disease-related anemia

30 Nov 2010
Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1

29 Nov 2010

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback